Indigenous knowledge holders became partners, not invisible informants
In the forests of the Agastya hills in 1987, a scientist named Palpu Pushpangadan encountered something that would outlast any laboratory finding: the quiet generosity of a tribal community sharing knowledge they had long been given no reason to trust. What began as a botanical survey became, over the following decade, a landmark reckoning with who owns traditional wisdom and who profits from it. Pushpangadan's work with the Kani tribe — translating their knowledge of the arogyapachcha plant into both a commercial health tonic and a formal benefit-sharing arrangement — offered the world a working answer to one of biodiversity law's most urgent questions. His life's work insists that science conducted without equity is incomplete.
- For generations, indigenous communities like the Kani watched their knowledge flow outward into research and commerce while nothing flowed back — Pushpangadan's encounter in 1987 exposed this silent extraction in vivid, personal terms.
- The arogyapachcha plant's remarkable anti-fatigue properties, once validated by laboratory science and protected by patents, suddenly carried enormous commercial and geopolitical stakes far beyond the Agastya hills.
- Pushpangadan pushed against institutional inertia by formally hiring Kani guides as paid consultants and insisting that license revenues be split equally — gestures that were small in scale but radical in precedent.
- The Kerala Kani Samudaya Kshema Trust, registered in 1997, gave the benefit-sharing arrangement a legal body, ensuring that royalties from the Jeevani tonic actually reached the community whose knowledge had made it possible.
- As wealthy nations argued that indigenous benefit-sharing was impractical, the Kani case stood as living proof otherwise, becoming a reference model in global negotiations under the Convention on Biological Diversity.
In 1987, ethnobiologist Palpu Pushpangadan entered the forests of the Agastya hills near Thiruvananthapuram on a routine documentation assignment. What changed everything was a small observation: the Kani tribal youth guiding him through the terrain showed no fatigue after hours of trekking, while the scientists were spent. The guides, cautious but eventually willing, revealed they were chewing fruits from a forest plant they called Arogyapachcha — the source of evergreen health. Pushpangadan tasted the berries. The effect was unmistakable.
Laboratory analysis at the Regional Research Laboratory in Jammu confirmed what the forest had already demonstrated. The plant, botanically identified as Trichopus zeylanicus travancoricus, contained glycolipids and non-steroidal polysaccharides with genuine immune-boosting and anti-fatigue properties. Patents were filed. By 1990, Pushpangadan had become director of the Tropical Botanic Garden and Research Institute in Thiruvananthapuram, and he assembled an unusually cross-disciplinary team — pharmacologists, phytochemists, biochemists, and Ayurvedic scholars — to develop the research further. By 1994, they had produced Jeevani, a health tonic blending the Kani plant with broader Ayurvedic knowledge.
What set Pushpangadan apart was his insistence that the people who had shared the knowledge be formally recognized as contributors. Between 1993 and 1998, two of the original Kani guides were hired as paid consultants. When the institute licensed the Jeevani technology to Arya Vaidya Pharmacy in 1996 for 10 lakh rupees and a 2 percent royalty on sales, Pushpangadan demanded an equal split with the Kani community. The Kerala Kani Samudaya Kshema Trust was registered in 1997 to receive and manage that share. It was imperfect — questions lingered about community representation and the trust's long-term durability — but benefits actually reached the people whose knowledge had been the foundation.
The arrangement arrived at a pivotal moment. The Convention on Biological Diversity, adopted at Rio in 1992, had established that nations of the Global South owned their genetic resources and deserved fair compensation — but offered no mechanism for how. The Kani case filled that gap before most countries had laws to enforce one. It became a global reference point, demonstrating that structured benefit-sharing was achievable even in the absence of perfect conditions, and it shaped how developing nations argued for indigenous intellectual property rights in international forums.
Pushpangadan's enduring contribution was not simply a plant discovery or an institutional achievement. It was the act of embedding equity into scientific practice itself — of insisting that traditional knowledge holders are partners, not invisible informants. From berries shared on a forest trail, he helped build a framework for justice that continues to shape how the world negotiates the relationship between biodiversity, indigenous wisdom, and the benefits that flow from both.
In 1987, two ethnobiologists named Palpu Pushpangadan and S. Rajasekharan walked into the forests of the Agastya hills near Thiruvananthapuram with a straightforward assignment: document the region's plants and their uses for the All India Coordinated Research Project on Ethnobiology. They were not prepared for what they would learn in the first few days of fieldwork.
The Kani tribal youth who guided them through the forest showed no fatigue after hours of trekking, while the scientists themselves were exhausted. When Pushpangadan asked why, the guides explained they were chewing fruits from a forest plant to restore their energy. The Kani were cautious about sharing this knowledge—indigenous wisdom had been taken before—but gradually they opened up. Pushpangadan and his team tasted the berries. The effect was real. The plant, which the Kani called Arogyapachcha, meaning the source of evergreen health, was later identified botanically as Trichopus zeylanicus travancoricus. What seemed like a casual exchange in the forest would reshape how science and indigenous communities could work together.
Samples went to the Regional Research Laboratory in Jammu for analysis. The results surprised everyone. The plant contained glycolipids and non-steroidal polysaccharides with immune-boosting and anti-fatigue properties—not the steroids researchers had expected. The science held up. Patents were filed. The plant mattered beyond the Agastya hills. By 1990, Pushpangadan had become director of the Tropical Botanic Garden and Research Institute in Thiruvananthapuram, and the arogyapachcha research moved with him. He assembled a team that crossed disciplines: pharmacologists, phytochemists, biochemists, and Ayurvedic scholars working together in ways that had not happened before at the institute.
What distinguished Pushpangadan's approach was not just the science. Between 1993 and 1998, two of the original Kani guides were formally hired as consultants and paid a monthly fee. It was a small gesture that carried enormous weight. These men were no longer invisible sources of information. They were recognized as contributors to the research itself. By 1994, the team had developed Jeevani, a health tonic that blended the Kani plant with broader Ayurvedic knowledge. Notably, the Kani had used only the fruit; Jeevani was made from the leaves, which made up just 13 to 15 percent of the final formulation. The rest came from other plants and traditional systems. This distinction would matter later in debates about who owned what.
In November 1996, the institute licensed the technology to Arya Vaidya Pharmacy in Coimbatore for a fee of 10 lakh rupees and a royalty of 2 percent on sales. Pushpangadan insisted on something radical: the money would be split equally between the institute and the Kani community. The Kerala Kani Samudaya Kshema Trust was registered in 1997 to manage the Kani share. It was not perfect—questions arose about who truly represented the community and whether the trust would endure—but it worked. Benefits actually flowed to the people whose knowledge had been the foundation.
The timing was crucial. The Convention on Biological Diversity had been adopted at Rio in 1992 and took effect in 1993, asserting that countries of the Global South owned their genetic resources and deserved fair compensation when those resources were used. But the treaty stated principles, not mechanisms. How would benefit-sharing actually happen? Who spoke for communities? How could traditional knowledge be honored without turning it into a commodity? Pushpangadan's Kani arrangement provided an answer before most countries had laws to enforce one. It became a reference point in global negotiations, proof that structured benefit-sharing was possible even when messy and imperfect. While wealthy nations argued that such arrangements were impractical, the Kani case showed otherwise. It shaped how developing countries argued for their rights in debates over intellectual property and biodiversity.
Pushpangadan's legacy rests not only on discovering a plant or building institutions, but on embedding equity into the practice of science itself. He translated an ethical commitment—that indigenous knowledge holders deserve recognition and payment—into actual structures that lasted. From berries shared on a forest trail emerged a global conversation about justice, knowledge, and who gets to benefit when traditional wisdom meets modern science. His work reminds us that protecting the living world depends not only on preserving plants and ecosystems, but on honoring and compensating the communities who have stewarded them for generations.
Notable Quotes
The Kani were cautious about sharing their knowledge, reflecting both the guarded nature of indigenous wisdom and the trust slowly built through engagement— Paraphrased from the source material
Pushpangadan proposed and successfully institutionalized a benefit-sharing arrangement whereby the licence fee and royalties would be divided equally between TBGRI and the Kani community— Paraphrased from the source material
The Hearth Conversation Another angle on the story
Why did Pushpangadan's approach feel so different from what had happened before?
Because he didn't treat the Kani as a source to extract information from and move on. He paid them. He hired them as consultants. He split the profits. Those seem like small things, but they were revolutionary in a field where indigenous knowledge had been treated as free material for scientists to use.
The Jeevani formulation used only 13 to 15 percent of the Kani plant. Does that undermine their claim to the knowledge?
That's the tension Pushpangadan had to navigate. The Kani knew about the fruit. Scientists developed a product from the leaves using broader Ayurvedic systems. Who owns that? He didn't try to hide the distinction. He was honest about what came from whom, which actually strengthened the case for benefit-sharing rather than weakening it.
The trust was created in 1997. Did it actually survive and deliver benefits over time?
The source doesn't detail what happened after the trust was established, but it notes that concerns about representativeness and viability were raised early on. The fact that it's described as an "enduring institutional mechanism" suggests it did persist, but the real test was whether the Kani community actually saw sustained benefit.
How did this one case change global policy?
It provided proof of concept right when the world needed it. The Convention on Biological Diversity was new. Developing countries were arguing that they deserved compensation for their genetic resources, but wealthy nations said it was impossible to implement. Pushpangadan showed it could be done. The Kani case became the example everyone pointed to.
What was the hardest part of what he did?
Probably holding the tension between all the competing interests—the institute's need for resources, the Kani's need for recognition and payment, the scientific drive to develop a product, the desire to honor traditional knowledge without commodifying it. There's no clean answer to any of those conflicts. He had to build institutions that could live with the messiness.